证券日报网12月9日讯汤臣倍健（300146）在12月9日回答调研者提问时表示，公司SKU较多，各产品间 复购率存在差异。今年主品牌线上推出的几大新品在拉动高消费人群增量方面表现较为亮眼。 ...

证券日报网12月9日讯汤臣倍健（300146）在12月9日回答调研者提问时表示，公司经销商数量近年来减 少的原因：主要是因为业务调整、经销商整合优化所致。鉴于公司持续探索新渠道、新品牌和新平台， 未来经销商的持续优化还是会存在。 ...

证券日报网12月9日讯汤臣倍健（300146）在12月9日回答调研者提问时表示，药店渠道的专业服务能力 是其他渠道不可替代的，公司将持续夯实产品力，通过加快药店全链路DDI数字化基建建设、推行新商 业配送模式等持续强化精细化运营能力和服务能力，夯实线下发展优势。 ...

证券日报网12月9日讯汤臣倍健（300146）在12月9日回答调研者提问时表示，山姆近年来增长较好，后 续公司会积极加强与相关高潜力商超连锁的合作，共同拓展线下的增长机会。 ...

（编辑 任世碧） 证券日报网12月9日讯 汤臣倍健在12月9日回答调研者提问时表示，今年，公司持续推动数字化战略项 目落地，强化数字化基建，提升销售管理、数据分析等系统能力；成立30周年专项工作小组，常态化推 动重要经营和管理质量强相关问题的解决及机制落实；持续优化组织架构，提升各业务线条精细化管理 能力，支持公司长期健康发展。 ...

（编辑 任世碧） 证券日报网12月9日讯 汤臣倍健在12月9日回答调研者提问时表示，抖音已成为VDS行业线上销售的第 一大平台且持续保持高速增长，天猫和京东仍占有较高市场份额；跨境电商保持较好增长。公司后续将 持续优化运营策略，加强社媒渗透，根据不同渠道的消费者需求和偏好推动主要品类迭代升级，优化策 略人群和品牌资产，持续提升线上运营效率，在抖音及跨境寻求增量。 ...

（编辑 任世碧） 证券日报网12月9日讯 汤臣倍健在12月9日回答调研者提问时表示，当前消费需求呈现日益多元化和个 性化的趋势，对产品的迭代需求也在增加，未来公司将围绕主要核心品类、结合不同渠道的需求特性进 行产品研发创新，为消费者提供更加多样化的产品选择。 ...

| 猫和京东仍占有较高市场份额；跨境电商保持较好增长。公司后续将持续 | | --- | | 优化运营策略，加强社媒渗透，根据不同渠道的消费者需求和偏好推动主 | | 要品类迭代升级，优化策略人群和品牌资产，持续提升线上运营效率，在 | | 抖音及跨境寻求增量。 | | Q：公司线上分平台的收入占比、公司旗下各品牌收入占比 | | 线上渠道中抖音平台约占两成，天猫和京东合计约占六成。主品牌收 | | 入占比超五成，健力多、lifespace 收入占比均超过 10%。 | | Q：今年消费者复购的情况如何 | | 公司 较多，各产品间复购率存在差异。今年主品牌线上推出的几 SKU | | 大新品在拉动高消费人群增量方面表现较为亮眼。 | | Q：公司经销商数量近年来减少的原因 | | 主要是因为业务调整、经销商整合优化所致。鉴于公司持续探索新渠 | | 道、新品牌和新平台，未来经销商的持续优化还是会存在。 | | Q：公司在市值管理上有何措施 | | 公司聚焦主业，致力于推动公司长期有质量发展，同时通过实施积极、 | | 持续、稳定的分红政策及回购等措施增强投资者回报。上市以来公司累计 | | 现金分红金额占累 ...

Core Insights - The pharmaceutical-grade fish oil market is experiencing significant growth due to its high purity levels of EPA and DHA, which are crucial for cardiovascular disease prevention and brain health maintenance [1][3][4] - The global demand for pharmaceutical-grade fish oil is projected to increase, with sales expected to reach 31,400 tons in 2024, an increase of 5.9% from 2023 [3][4] - In China, the pharmaceutical-grade fish oil market is also expanding, with sales anticipated to reach 5,500 tons in 2024, reflecting a growth of 25% from the previous year [4] Industry Definition and Characteristics - Pharmaceutical-grade fish oil is derived from fatty fish and is characterized by its high concentration of omega-3 fatty acids, specifically EPA and DHA, which are validated for specific medical purposes [2][3] - Unlike regular dietary supplements, pharmaceutical-grade fish oil is a prescription-level treatment product with strong clinical evidence supporting its efficacy [2] Current Industry Status - The pharmaceutical-grade fish oil industry is witnessing a surge in demand driven by increasing health awareness among consumers, an aging population, and rising chronic disease rates [3][4] - The market is expected to see a steady increase in sales, with global sales projected to reach approximately 31,600 tons by 2025 [3] Industry Chain - The industry chain consists of upstream raw materials such as herring, mackerel, sardines, and tuna, which are processed into crude fish oil [5] - The midstream involves the production of pharmaceutical-grade fish oil, which has the highest technical barriers [5] - Downstream applications include pharmaceuticals, clinical nutrition, and high-end dietary supplements [5] Development Environment and Policies - The pharmaceutical-grade fish oil industry in China is supported by national policies aimed at promoting and regulating the sector, including standards for food safety and specific regulations for omega-3 fish oil products [6][7] Competitive Landscape - The Chinese pharmaceutical-grade fish oil market is characterized by competition among international pharmaceutical giants, leading domestic raw material and manufacturing companies, and health supplement brands [7][9] - The market is consolidating as stricter regulations and higher technical barriers drive competition towards leading players [7] Development Trends - The industry is moving towards a new phase characterized by high quality, strong evidence, precision, and globalization, with trends indicating a shift towards more precise, diversified, and evidence-based applications [11]

证券日报网讯12月4日，汤臣倍健（300146）在互动平台回答投资者提问时表示，公司财务数据及具体 经营情况请关注公司定期报告。 ...